Treatment of Infectious Complications of the Hematopoietic Syndrome

  • Alexandre B. Oliveira


From a strictly therapeutic point of view, bone marrow failure resulting from irradiation presents three main challenges to the clinician: (1) to correct any metabolic disturbances, either of the hydroelectrolytic compartment or of a nutritional nature; (2) to compensate for cytopenias, particularly of granulocytes and platelets; and (3) to prevent or treat infections. These goals can be achieved only through supportive, substitutive, or compensative therapies. In this chapter, I summarize the principal therapies that have been adopted for preventing and treating the infectious complications of the hematopoietic syndrome—complications that derive basically from transient granulocytopenia, which usually lasts for about 2 weeks. Severe bone marrow failure appears when significant body volumes receive doses of about 4-6 Gy within a short period of time. The clinician must bear in mind that the hematopoietic syndrome can put the life of an irradiated person at risk. Patients with severe granulocytopenia (less than 100/pL) tend to develop early and possibly fatal infectious fevers. Despite the possibility that a concomitant hemorrhage might occur, which certainly would contribute to an increase in the mortality rate, it has seldom been observed in accidentally irradiated persons. Infectious complications are responsible for most fatalities. The basic rules adopted for preventing and treating infectious complications observed in accidentally irradiated persons do not differ substantially from those used for treating cancer patients who present granulocytopenia as a consequence of either the underlying disease or their chemotherapy or radiotherapy regimens.


Infectious Complication Bone Marrow Failure Febrile Neutropenic Patient Radiation Accident Granulocyte Transfusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schimpff, S. C., Satterlee, W., Young, V. M., et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Eng J Med 284: 1061–1065, 1971.CrossRefGoogle Scholar
  2. 2.
    Hubner, K. F., and Fry, S. A., Eds. The Medical Basis for Radiation Accident Preparedness. Elsevier North Holland, Inc., New York, 1980.Google Scholar
  3. 3.
    Rubin, M., Hathorn, J. W., and Pizzo, P. A. Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 6 (2): 167–184, 1988.Google Scholar
  4. 4.
    Pizzo, P. A., Hathorn, J. W., Hiemenz, J., et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Eng J Med 315 (9): 552–558, 1986.CrossRefGoogle Scholar
  5. 5.
    Dejace, P., and Klastersky, J. Comparative review of combination therapy: Two beta-lactams versus beta-lactam plus aminoglycoside. Am J Med 80 (6B): 29–38, 1986.PubMedCrossRefGoogle Scholar
  6. 6.
    Wade, J. C., Standiford, H. C., Drusano, G. L., et al. Potential of imipenem as a single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer. Am J Med 78 (5A): 62–72, 1985.PubMedCrossRefGoogle Scholar
  7. 7.
    Karp, J. E., Merz, W. G., Hendricksen, C., et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 106: 1–7, 1987.PubMedCrossRefGoogle Scholar
  8. 8.
    Rubin, M., Hathorn, J. W., Marshall, D., et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108: 30–35, 1988.PubMedCrossRefGoogle Scholar
  9. 9.
    Wong, K. K., and Hirsch, M. S. Herpes virus infections in patients with neoplastic diseases. Diagnosis and therapy. Am J Med 76: 464–478, 1984.PubMedCrossRefGoogle Scholar
  10. 10.
    Winston, D. J., Ho, W. G., and Gale, R. P. Therapeutic granulocyte transfusions for documented infections. Ann Intern Med 97: 509–515, 1982.PubMedCrossRefGoogle Scholar
  11. 11.
    Butturini, A., DeSouza, P. C., Gale, R. P., et al. Use of recombinant granulocyte-macrophage colony-stimulating factor in the Brazil radiation accident. Lancet 11: 471–475, 1988.CrossRefGoogle Scholar
  12. 12.
    Grabstein, K. H., Urdal, D. L., Tushiaski, R. J., et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232: 506–508, 1986.PubMedCrossRefGoogle Scholar
  13. 13.
    Weisbart, R. H., Golde, D. W., Clark, S. C., et al. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature 314: 361–363, 1985.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Alexandre B. Oliveira
    • 1
  1. 1.Institudo Nuclebra de Seguridade SocialRio de JaneiroBrazil

Personalised recommendations